C
Chris Parker
Researcher at Institute of Cancer Research
Publications - 479
Citations - 35757
Chris Parker is an academic researcher from Institute of Cancer Research. The author has contributed to research in topics: Prostate cancer & Radiation therapy. The author has an hindex of 79, co-authored 422 publications receiving 30260 citations. Previous affiliations of Chris Parker include The Royal Marsden NHS Foundation Trust & University of Toronto.
Papers
More filters
Journal ArticleDOI
A more selective approach to prostate biopsy could be a safe and effective form of prostate cancer ‘prevention’
TL;DR: Lead times and overdetection due to prostatespecific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer: Estimates from the JNCI 2003; 95 : 868–78.
Journal Article
Effects of radium-223 dichloride (Ra-223) on health-related quality of life (QOL) outcomes in the phase 3 ALSYMPCA study in patients with castration-resistant prostate cancer (CRPC) and bone metastases
Chris Parker,Daniel Heinrich,David Bottomley,Peter Hoskin,Lars Franzén,Arne Solberg,V. Pawar,Jonathan Reuning-Scherer,C.G. O'Bryan-Tear,Stinabritt Nilsson +9 more
TL;DR: Effects of radium-223 dichloride (Ra-223) on health-related quality of life (QOL) outcomes in the phase 3 ALSYMPCA study in patients with castration-resistant prostate cancer and bone metastases is studied.
Journal ArticleDOI
Standard and hypofractionated dose escalation to intraprostatic tumour nodules in localised prostate cancer: 5 year efficacy and toxicity in the DELINEATE trial.
Alison Tree,Laura Satchwell,Emma Alexander,I Blasiak-Wal,N M Desouza,Annie Gao,E. Greenlay,Helen McNair,Chris Parker,James Talbot,David P. Dearnaley,Julia Murray +11 more
TL;DR: DELINEATE as discussed by the authors is a single center phase 2 multicohort study including standardly fractionated (cohort A: 74 Gy/37F to prostate and seminal vesicles [PSV]; cohort C 74 Gy 37F to PSV plus 60 Gy/39F to pelvic lymph nodes).